Please provide your email address to receive an email when new articles are posted on . The 7-year intracranial progression free-survival among patients treated with combination therapy was 42%.

A Prescription Drug User Fee Act target date of April 21, 2025 has been assigned to the application. Findings showed the immunotherapy combination significantly improved overall survival (OS; primary ...

Induction combination immunotherapy followed by chemoradiation therapy appears to be an effective bladder-sparing treatment in MIBC. Combined neoadjuvant treatment with ipilimumab and nivolumab ...

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months. HealthDay News — For patients with resected ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to ipilimumab prolonged survival for patients with advanced melanoma. Nivolumab ...

Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall survival (OS) when treated with single-agent ipilimumab (Yervoy), a small ...

Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study Adults with stage IB-IIIA (American Joint ...

Final results from the TITAN-RCC trial demonstrate improvements in objective response rates compared with nivolumab monotherapy. Adaptive treatment with nivolumab plus ipilimumab improves outcomes ...

First-line nivolumab plus ipilimumab significantly improved survival versus lenvatinib or sorafenib in patients with unresectable liver cancer. The median overall survival of 23.7 months with the ...

Limited Resection Versus Lobectomy for Older Patients With Early-Stage Lung Cancer: Impact of Histology The approved dose of ipilimumab is 3 mg/kg infused over 90 minutes; however, in clinical trials, ...

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free ...

Adding ipilimumab to standard-dose nivolumab improves progression-free and overall survival in advanced melanoma. Ipilimumab plus nivolumab is assumed to have the same benefit in other advanced ...